Literature DB >> 19803766

Empirical antimicrobial therapy for bloodstream infection due to methicillin-resistant Staphylococcus aureus: no better than a coin toss.

Carrie A Herzke1, Luke F Chen, Deverick J Anderson, Yong Choi, Daniel J Sexton, Keith S Kaye.   

Abstract

BACKGROUND: Despite the high prevalence of methicillin-resistant Staphylococcus aureus (MRSA) infection in the hospital, the proportion of patients with MRSA bacteremia who receive appropriate empirical therapy remains suboptimal.
OBJECTIVE: To investigate the proportion of patients with MRSA bloodstream infection (BSI) who received appropriate empirical antibiotic therapy and to identify risk factors associated with receipt of appropriate empirical therapy.
METHODS: We studied a cohort of patients from 10 hospitals. The primary outcome was the proportion of patients who received appropriate empirical antibiotic therapy for MRSA BSI. Appropriate therapy was defined as receipt of daptomycin, linezolid, quinupristin-dalfopristin, or vancomycin within 1 calendar day after the first blood culture result positive for S. aureus (ie, before antimicrobial susceptibilities were known). Multivariable logistic regression was used to determine variables associated with receipt of appropriate empirical therapy.
RESULTS: The study included 562 patients with MRSA BSI. The mean (+/-standard deviation) age of the patients was 64 +/- 16 years, and 288 (51.2%) were male. Only 291 (51.8%) patients received appropriate empirical therapy. Patients were more likely to receive appropriate therapy if they required hemodialysis (odds ratio [OR], 1.36 [95% confidence interval {CI}, 1.00-1.85]), had undergone knee or hip arthroplasty (OR, 3.04 [95% CI, 1.21-7.6]), had a central venous catheter at admission (OR, 1.72 [95% CI, 1.01-2.93]), or had a McCabe score of 1 at admission (OR, 1.83 [95% CI, 1.16-2.83]). Bowel incontinence (OR, 0.41 [95% CI, 0.19-0.92]) and BSIs categorized as primary (OR, 0.41 [95% CI, 0.27-0.63]) were associated with a decreased likelihood of receiving appropriate empirical therapy.
CONCLUSIONS: Only half of patients with MRSA BSI received appropriate empirical therapy. Factors associated with receiving appropriate empirical antibiotics included the presence of a central venous catheter at admission and a history of joint arthroplasty. Surprisingly, prior MRSA infection was not predictive of receipt of appropriate antimicrobial therapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19803766     DOI: 10.1086/606163

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


  5 in total

1.  Use of the Accelerate Pheno System for Identification and Antimicrobial Susceptibility Testing of Pathogens in Positive Blood Cultures and Impact on Time to Results and Workflow.

Authors:  Angella Charnot-Katsikas; Vera Tesic; Nedra Love; Brandy Hill; Cindy Bethel; Sue Boonlayangoor; Kathleen G Beavis
Journal:  J Clin Microbiol       Date:  2017-12-26       Impact factor: 5.948

2.  Comparison of novel approaches for expedited pathogen identification and antimicrobial susceptibility testing against routine blood culture diagnostics.

Authors:  L Knabl; S Huber; C Lass-Flörl; S Fuchs
Journal:  Lett Appl Microbiol       Date:  2021-05-06       Impact factor: 2.858

3.  Survival Benefit of Empirical Therapy for Staphylococcus aureus Bloodstream Infections in Infants.

Authors:  Joshua T Thaden; Jessica E Ericson; Heather Cross; Stephen P Bergin; Julia A Messina; Vance G Fowler; Daniel K Benjamin; Reese H Clark; Christoph P Hornik; P Brian Smith
Journal:  Pediatr Infect Dis J       Date:  2015-11       Impact factor: 3.806

4.  Impact of Location of Acquisition of Gram-Positive Bloodstream Infections on Clinical Outcomes Among Patients Admitted to Community Hospitals.

Authors:  Julia A Messina; Rebekah W Moehring; Kenneth E Schmader; Deverick J Anderson
Journal:  Infect Drug Resist       Date:  2020-08-25       Impact factor: 4.003

5.  Comparison of quick SOFA and SIRS scales at the bedside of patients with Staphylococcus aureus bacteremia

Authors:  Óscar García; Tatiana Álvarez; Santiago Granados; Vanessa Garzón; Santiago González
Journal:  Biomedica       Date:  2020-05-01       Impact factor: 0.935

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.